Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Lymphoid 1Dermatologic 1

Conditions

Melanoma 3Prostatic Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

pembrolizumab 10Nivolumab 5Gemcitabine 4durvalumab 3Specimen Handling 3Sirolimus 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cryosurgery 3Cisplatin 3Blood Specimen Collection 3tremelimumab 2temsirolimus 2pertuzumab 2pegilodecakin 2enzalutamide 2cabozantinib 2alvocidib 2Vorinostat 2Trastuzumab 2Ritonavir 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Interleukin-2 2Cyclophosphamide 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × sepantronium × Dermatologic × Clear all
NCT00818480 2015-09-04

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Astellas Pharma Inc

Phase 2 Completed
10 enrolled
DermatologicGenitourinaryLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡